Table 3.
Cytotoxic Concentration (CC)50 of Ruthenium compounds measured against Jurkat and SUP-T1 human cell lines analyzed by flow cytometry.
| CC50 (µM) a |
|||||||
|---|---|---|---|---|---|---|---|
| Cell line | 1 | 2 | 3 | 4 | 5 | 6 | CQDP |
| SUP-T1 | 128 | 88 | 54 | 75 | 70 | Non toxicb | 130 |
| Jurkat | 153 | 90 | 81 | 86 | 77 | 129 | 95 |
CC50 is defined as the concentration of drug required to disrupt the plasma membrane of 50% of cell population, compared to untreated cells, after 20 h of incubation. Cells with compromised plasma membrane were monitored using propidium iodide (PI) and flow cytometry.
Even when SUP-T1 cells, a human T-lymphoma cell line, were exposed to 100 µM of [Ru(η6-arene)(en)Cl]PF6 (6), the cytotoxicity measured was similar to that of untreated control cells. All values represent average obtained from triplicates.